Poxel S.A. (POXEL.PA)
EUR 0.38
(-22.56%)
EUR 0.38
(-22.56%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 28.76 Million EUR | 31.39% |
| 2022 | 21.89 Million EUR | -38.85% |
| 2021 | 35.8 Million EUR | -2.32% |
| 2020 | 36.65 Million EUR | -28.45% |
| 2019 | 51.22 Million EUR | -17.46% |
| 2018 | 62.06 Million EUR | 128.25% |
| 2017 | 27.19 Million EUR | 11.66% |
| 2016 | 24.35 Million EUR | 106.72% |
| 2015 | 11.78 Million EUR | 70.83% |
| 2014 | 6.89 Million EUR | -5.18% |
| 2013 | 7.27 Million EUR | 2.15% |
| 2012 | 7.11 Million EUR | -17.99% |
| 2011 | 8.68 Million EUR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 FY | - EUR | -100.0% |
| 2023 Q4 | 19.26 Million EUR | 0.0% |
| 2023 Q2 | -16.57 Million EUR | 0.0% |
| 2022 FY | 21.89 Million EUR | -38.85% |
| 2022 Q4 | 9.99 Million EUR | 0.0% |
| 2022 Q2 | 654 Thousand EUR | 0.0% |
| 2021 FY | 35.8 Million EUR | -2.32% |
| 2021 Q2 | 21.41 Million EUR | 0.0% |
| 2021 Q4 | 16.21 Million EUR | 0.0% |
| 2020 Q2 | 19.78 Million EUR | 0.0% |
| 2020 FY | 36.65 Million EUR | -28.45% |
| 2020 Q4 | 18.83 Million EUR | 0.0% |
| 2019 FY | 51.22 Million EUR | -17.46% |
| 2019 Q1 | -13.02 Million EUR | -142.11% |
| 2019 Q2 | 30.41 Million EUR | 333.42% |
| 2019 Q4 | 24.76 Million EUR | 0.0% |
| 2018 FY | 62.06 Million EUR | 128.25% |
| 2018 Q4 | 30.94 Million EUR | 0.0% |
| 2018 Q1 | -15.25 Million EUR | -185.22% |
| 2018 Q2 | 30.43 Million EUR | 299.53% |
| 2017 Q2 | 9.67 Million EUR | 240.51% |
| 2017 FY | 27.19 Million EUR | 11.66% |
| 2017 Q4 | 17.89 Million EUR | 0.0% |
| 2017 Q1 | -6.88 Million EUR | -156.95% |
| 2016 Q1 | 18.37 Thousand EUR | -99.73% |
| 2016 Q4 | 12.09 Million EUR | 0.0% |
| 2016 FY | 24.35 Million EUR | 106.72% |
| 2016 Q2 | 12.24 Million EUR | 66531.58% |
| 2015 Q2 | 4.96 Million EUR | 48684.53% |
| 2015 FY | 11.78 Million EUR | 70.83% |
| 2015 Q4 | 6.74 Million EUR | 66184.32% |
| 2015 Q3 | 10.17 Thousand EUR | -99.8% |
| 2015 Q1 | 10.17 Thousand EUR | -99.66% |
| 2014 Q4 | 2.95 Million EUR | 43577.18% |
| 2014 Q3 | 6762.25 EUR | -99.94% |
| 2014 Q2 | 10.8 Million EUR | 159702.42% |
| 2014 Q1 | 6762.25 EUR | -99.96% |
| 2014 FY | 6.89 Million EUR | -5.18% |
| 2013 FY | 7.27 Million EUR | 2.15% |
| 2013 Q4 | 17.07 Million EUR | 359174.47% |
| 2013 Q2 | 3.44 Million EUR | 72297.67% |
| 2013 Q3 | 4753.75 EUR | -99.86% |
| 2013 Q1 | 4753.75 EUR | 0.0% |
| 2012 Q3 | 5035.75 EUR | 0.0% |
| 2012 FY | 7.11 Million EUR | -17.99% |
| 2012 Q1 | 5035.75 EUR | 0.0% |
| 2012 Q2 | 5035.75 EUR | 0.0% |
| 2012 Q4 | 4753.75 EUR | -5.6% |
| 2011 Q2 | 4652.00 EUR | 0.0% |
| 2011 FY | 8.68 Million EUR | 0.0% |
| 2011 Q1 | 4652.00 EUR | 0.0% |
| 2011 Q4 | 5035.75 EUR | 8.25% |
| 2011 Q3 | 4652.00 EUR | 0.0% |
| 2010 Q4 | 4652.00 EUR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| ABIONYX Pharma SA | 4.17 Million EUR | -588.652% |
| ABIVAX Société Anonyme | 127.37 Million EUR | 77.417% |
| Adocia SA | 15.62 Million EUR | -84.049% |
| Aelis Farma SA | 18.81 Million EUR | -52.851% |
| Biophytis S.A. | 14.33 Million EUR | -100.691% |
| Advicenne S.A. | 8.21 Million EUR | -250.152% |
| genOway Société anonyme | 16.73 Million EUR | -71.852% |
| IntegraGen SA | 5.35 Million EUR | -437.411% |
| Medesis Pharma S.A. | 1.56 Million EUR | -1738.522% |
| Neovacs S.A. | 10.34 Million EUR | -178.096% |
| NFL Biosciences SA | 4.37 Million EUR | -557.583% |
| Plant Advanced Technologies SA | 2.76 Million EUR | -940.382% |
| Quantum Genomics Société Anonyme | 1.71 Million EUR | -1574.365% |
| Sensorion SA | 27.05 Million EUR | -6.326% |
| Theranexus Société Anonyme | 3 Million EUR | -857.242% |
| TME Pharma N.V. | 5.49 Million EUR | -423.285% |
| Valbiotis SA | 9.86 Million EUR | -191.468% |
| TheraVet SA | 1.64 Million EUR | -1649.363% |
| Valerio Therapeutics Société anonyme | 20.32 Million EUR | -41.56% |
| DBV Technologies S.A. | 89.4 Million EUR | 67.826% |
| Genfit S.A. | 54.8 Million EUR | 47.513% |
| GeNeuro SA | 14.35 Million EUR | -100.351% |
| Innate Pharma S.A. | 64.57 Million EUR | 55.451% |
| Inventiva S.A. | 120.18 Million EUR | 76.066% |
| MaaT Pharma SA | 21.59 Million EUR | -33.184% |
| MedinCell S.A. | 32.92 Million EUR | 12.627% |
| Nanobiotix S.A. | 58.92 Million EUR | 51.185% |
| OSE Immunotherapeutics SA | 23.58 Million EUR | -21.942% |
| GenSight Biologics S.A. | 32.66 Million EUR | 11.926% |
| Transgene SA | 31.23 Million EUR | 7.896% |
| Valneva SE | 134.92 Million EUR | 78.681% |